Cover Image

The implementation and side effect management of immune checkpoint inhibitors in gynecologic oncology: a JAGO/NOGGO survey

The integration of immune checkpoint inhibitors (ICIs) into routine gynecologic cancer treatment requires a thorough understanding of how to manage immune-related adverse events (irAEs) to ensure patient safety. However, reports on real-world clinical experience in the management of ICIs in gynecolo...

Full description

Saved in:
Bibliographic Details
Main Authors: Riedel, Maximilian (Author) , Herrmann, Helene (Author) , Bartl, Thomas (Author) , Rossner, Anna-Maria (Author) , Tatzber, Anna (Author) , Flethe, Chiara (Author) , Zocholl, Dario (Author) , Schmalfeldt, Barbara (Author) , Sehouli, Jalid (Author) , Pietzner, Klaus (Author)
Format: Article (Journal)
Language:English
Published: 29 January 2025
In: BMC cancer
Year: 2025, Volume: 25, Pages: 170-1-170-9
ISSN:1471-2407
DOI:10.1186/s12885-025-13432-5
Online Access:Verlag, kostenfrei, Volltext: https://doi.org/10.1186/s12885-025-13432-5
Get full text
Author Notes:Maximilian Riedel, Helene Herrmann, Thomas Bartl, Anna-Maria Rossner, Anna Tatzber, Chiara Flethe, Dario Zocholl, Barbara Schmalfeldt, Jalid Sehouli and Klaus Pietzner
Description
Summary:The integration of immune checkpoint inhibitors (ICIs) into routine gynecologic cancer treatment requires a thorough understanding of how to manage immune-related adverse events (irAEs) to ensure patient safety. However, reports on real-world clinical experience in the management of ICIs in gynecologic oncology are very limited. The aim of this survey was to provide a real-world overview of the experiences and the current state of irAE management of ICIs in Germany, Switzerland, and Austria.
Item Description:Gesehen am 02.10.2025
Physical Description:Online Resource
ISSN:1471-2407
DOI:10.1186/s12885-025-13432-5

Similar Items